Innate Pharma SA
IPHANasdaq
$1.75
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↓ -2.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Innate Pharma S.A. discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the. treatment of cutaneous T-cell and peripheral T-Cell lymphoma. Its products include Monalizumab, an immune checkpoint inhibitor that is in. Phase III clinical trial to treat colorectal and lung cancer.
- CEO
- Mondher Mahjoubi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 220
- Website
- innate-pharma.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
May 19, 2026
May 13, 2026
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.